Objective The use of intravenous in-line filters is effective for the mechanical removal of large particles, precipitates, bacteria, fungi, large lipid globules, and air. However, the routine use of in-line filters remains controversial. Many patients with hematological diseases frequently suffer from bloodstream infections (BSIs) with fatal outcomes. Methods The year before cessation of an in-line filter was defined as the "filter period" and the year after its cessation was defined as the "non-filter period." The number of central line-associated bloodstream infections (CLABSIs), which are defined through surveillance, the catheter utilization rate, the number of patient deaths within 7 days after removal of the central venous catheters (CVCs), and the overall survival rate following CVC insertion were measured. Results During both periods, 84 patients had a total of 140 CVCs with a total number of catheter days of 3,407. There were 10 CVCs with CLABSIs, and the overall CLABSI rate was 2.9/1,000 catheter days, including 4 CVCs with CLABSIs (2.5/1,000 catheter days) during the filter period and 6 CVCs with CLABSIs (3.3/1,000 catheter days) during the non-filter period. The CLABSI rate, catheter utilization rate, and mortality did not differ significantly between the two periods. The only independent variable that was found to be significantly associated with the development of CLABSIs was a neutrophil count of <500×10 6 /L (p<0.05). Conclusion Our study revealed that the cessation of in-line filters from CVCs does not significantly influence the incidence of BSIs and mortality in patients with hematological disease. To confirm our results, however, a large-scale randomized controlled study is warranted.
Introduction
The use of in-line filters in peripheral and central venous infusion systems is effective for the mechanical removal of large particles, precipitates, bacteria, fungi, large lipid globules, and air. In particular, the administration of particles through infusion solutions can sometimes result in adverse effects, such as physical occlusion, inflammatory responses, neoplastic responses, and antigenic responses (1) . Some reports on pediatric care units have described that in-line filters reduce the overall complication rate and length of stay on pediatric care unit (2) ; in addition, they also reduce respiratory, renal, and hematological dysfunctions (3) and thrombus formation (4) by preventing particle infusion. In several reviews and guidelines, in-line filters are recommended solely for immunosuppressed patients, newborns, and children (1, 5) . On the other hand, in regard to the use of in-line filters in central venous catheters (CVCs) to prevent bloodstream infections (BSIs), other reviews and guidelines take a negative viewpoint (6) (7) (8) . A prospective controlled study for newborn infants showed that in-line filters in CVCs significantly reduced clinical sepsis and thrombosis (4); whereas, two other prospective studies from pediatric and neonatal intensive care units revealed that in-line filters in CVCs could not reduce the incidence of sepsis (9, 10). Thus, the routine use of in-line filters remains controversial (1, 5, 6, 11) . In fact, the 2002 guidelines for intravascular catheter-related bloodstream infections (CRBSIs) from the Centers for Disease Control and Prevention recommend the following: "for reducing the risk for CRBSI, no strong recommendation can be made in favor of using in-line filters." as category 1A (8) . Moreover, in the revised 2011 guidelines, all comments regarding in-line filters were deleted (12) . Thus, no legally binding rules exist for using inline filters in parenteral nutrition.
Many patients with hematological diseases are immunosuppressed and frequently suffer from BSIs with fatal outcomes. However, no study has so far verified the use of inline filters in CVCs to reduce BSI in patients with hematological diseases. We herein describe the effect of the cessation of in-line filters in CVCs for incidences of central lineassociated bloodstream infections (CLABSIs), which are defined as a surveillance and mortality in a hematology ward at our hospital.
Materials and Methods

Clinical setting
Our institution is a 99-bed general hospital in Japan, with a 30-bed South Ward for patients with hematological diseases. At our institution, autologous stem-cell transplantation, but not allogeneic transplantation, is performed.
Study design
At our hospital, the use of in-line filters in CVCs was ceased in June 2013, based on a decision taken by the hospital infection control committee. The year before the removal of in-line filters from June 1, 2012 to May 31, 2013 was defined as the "filter period" and the year after their cessation from June 1, 2013 to May 31, 2014 was defined as the "non-filter period." During both periods, a CVC line that was equipped with closed, needleless connectors was used and replaced every seven days. During the filter period, a Safioflow Infusion Set with an in-line filter of a 0.2-micron pore size (TOP Corporation, Tokyo, Japan) was used. The intravenous administration set consisted of stopcocks, in-line filters, and stopcocks from the indwelling CVC. Infusions that could not be passed through the in-line filter, such as lipid-containing admixtures, were administered through the stopcock at the proximal end. During the nonfilter period, a Surplug Solution Administration Set without an in-line filter (TERUMO, Tokyo, Japan) was used. During both periods, blood transfusions and blood products were infused through a peripheral intravenous catheter, which was inserted in addition to a CVC as a general rule. Parenteral nutrition and chemotherapy drugs that were infused through the CVCs were prepared within an aseptic pharmacy unit. When inserting the CVC, maximal barrier precautions were applied to all. A sterile, transparent, semipermeable dressing was used to cover the catheter site and it was replaced every seven days following disinfection with povidone-iodine. Furthermore, when bacteremia or febrile neutropenia were suspected in a patient, a blood specimen was promptly submitted for culture. Outcome surveillance, including the number of CLABSIs per 1,000 catheter days and catheter utilization rate (days of catheter use divided by total inpatient days), was measured. CLABSIs must meet at least one of the following criteria: (1) A known pathogen is cultured from one or more blood cultures from a patient, and the pathogen is not related to an infection at any other site. (2) A patient experiences at least one of the following signs or symptoms: fever, chills, or hypotension; the signs, symptoms, and positive laboratory results are not related to infection at another site; and a common skin contaminant (i.e., Corynebacterium spp., Bacillus spp., Propionibacterium spp., coagulasenegative staphylococci, viridans group streptococci, Aerococcus spp., and Micrococcus spp.) is cultured from two or more blood cultures taken on separate occasions (13) . Blood cultures submitted within the first 48 hours following CVC insertion were excluded. To evaluate mortality, the number of patient deaths within seven days after removal of the CVCs and the overall survival rate following CVC insertion were measured. The follow-up period of the overall survival analysis was defined as six months following the time of the CVC insertion. The following clinical data were collected and reviewed for all patients with indwelling CVCs who were hospitalized at the hematology ward during the filter and non-filter periods: age at insertion; sex; diseases (acute leukemia, malignant lymphoma, myelodysplastic syndrome, multiple myeloma, myeloproliferative neoplasm, and other diseases); minimum neutrophil count during catheterization; purpose of the CVC insertions (chemotherapy, securing vascular access, or intravenous hyperalimentation); insertion sites (subclavian vein, internal jugular vein, femoral vein, or cutaneous vein in the cubital region for peripherally inserted central catheters); duration of catheterization; administration of corticosteroids as cytotoxic agents, immunosuppressive therapy, or antiemetics. This study was approved by the hospital ethics committee. For publication of the results, approval of the in-hospital ethical review board was obtained.
Statistics
A chi-square analysis of the trend was used to assess temporal changes in the infection rate and the catheter utilization rate. Fisher's exact probability test was applied to the between-two-groups univariate analysis of categorical data. The overall survival curves were determined by the KaplanMeier method. To compare any differences between the sur- vival curves, the log-rank test was used. A logistic regression analysis was performed to investigate the influences of some factors as a multivariate analysis. A p value of less than 0.05 was considered to be statistically significant. All statistical analyses were performed using the EZR software program (Saitama Medical Centre, Jichi Medical University, Japan; http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/stat medEN.html; Kanda, 2012) , which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 2.13.0). More precisely, EZR is a modified version of R commander (version 1.6-3) that was designed to add frequently used statistical functions in biostatistics (14) .
Results
Patient characteristics
During the filter and non-filter periods, overall the 84 patients had a total of 140 CVCs, including 68 CVCs during the filter period and 72 CVCs during the non-filter period.
The total number of catheter days was 3,407, including 1,606 catheter days during the filter period and 1,801 catheter days during the non-filter period. The patient characteristics are given in Table 1 . No clinical factors showed any significant differences between both periods.
CLABSI rate, catheter utilization rate, and mortality in the filter and non-filter periods
The CLABSI rates and the catheter utilization rates are given in Table 2 . During both periods, 10 CVCs with CLABSIs occurred in nine patients and the overall CLABSI rate was 2.9/1,000 catheter days [95% confidence interval (CI), 1.1-4.8/1,000 catheter days], including four CVCs with CLABSIs (2.5/1,000 catheter days, 95% CI 0.1-4.9/1,000 catheter days) during the filter period and six CVCs with CLABSIs (3.3/1,000 catheter days, 95% CI 0.7-6.0/1,000 catheter days) during the non-filter period. The overall catheter utilization rate was 23.1%, including 18.6% during the filter period and 29.4% during the non-filter period. The CLABSI rate and catheter utilization rate between the filter and non-filter periods were not significantly different ac- cording to a chi-square analysis. The number of patient deaths within seven days after removal of the CVCs was 14 (including 11 patients older than 65 years old) in the filter period and 16 (including 12 patients older than 65 years old) in the non-filter period. These numbers were not significantly different in the chi-square analysis (Table 3) . Using the log-rank test, the overall patient survival rate from CVC insertions were not significantly different between the filter and non-filter periods (Figure) .
Characteristics of CVCs with CLABSIs
All 10 CVCs with CLABSIs in both the periods were inserted for chemotherapy. Among these patients, no findings were found that suggested the presence of any peripheral catheter-related infections. For the filter period, all four CVCs with CLABSIs were inserted in patients with acute leukemia; three of these CVCs were inserted via the internal jugular vein and one CVC via the subclavian vein. Among the six CVCs with CLABSIs in the non-filter period, three CVCs were inserted in patients with acute leukemia; three were inserted in patients with malignant lymphoma; four of these CVCs were inserted via the internal jugular vein and two CVCs via the subclavian vein.
Microorganisms detected in CLABSIs
In the filter period, Pseudomonas aeruginosa, Enterococcus faecalis, Pseudomonas fluorescens, and Streptococcus oralis were each detected once in one patient. In the nonfilter period, Enterobactor cloacae was detected three times in three different patients and Escherichia coli, Staphylococcus aureus, and Candida albicans were each detected once in one patient.
Risk factors associated with CLABSIs
According to a univariate analysis, a neutrophil count of less than 500×10 6 /L during catheterization and an age of less than 65 years at the time of CVC insertion were identified as variables significantly associated with the development of CLABSIs (p<0.01 and p<0.05, respectively) (Table 4). These two variables associated with CLABSIs in the univariate analysis were then entered into a multivariate logistic regression analysis. Table 5 shows a neutrophil count of less than 500×10 6 /L to be the only variable independently associated with the development of CLABSIs (p<0.05).
Discussion
Our study revealed that the cessation of in-line filters did not significantly influence the incidence of CLABSIs in a hematology ward. Thus, the use of in-line filters might not be essential to help reduce the number of BSIs in patients with hematological diseases. On the other hand, nonfiltration is not directly associated with mortality, suggesting that CVCs without filters may be used for patients with hematological diseases. Meanwhile, the incidence of CLABSIs increased 1.3 times after cessation of the in-line filters. However, there are some advantages of discontinuing in-line filters, such as easier administration of infusions that cannot pass through in-line filters, less frequent replacement of infusion systems due to obstruction of in-line filters, and a lower cost associated with such infusion systems.
Univariate and multivariate analyses indicated that a neutrophil count less than 500×10 6 /L is an independent risk factor influencing CLABSIs; whereas, the patients' ages at the time of insertion, diseases, purpose of CVC insertions (chemotherapy or not), insertion sites, and duration of catheterization were not independent risk factors influencing CLABSIs. Neutropenia has been identified as a risk factor for CRBSIs (15) (16) (17) . Therefore, to reduce the risk of BSIs in patients with neutropenia, the use of CVCs should be carefully managed by use of granulocyte-colony stimulating factor or by avoiding long-term CVC insertion, as far as possible. In a report describing BSIs in patients with hematological diseases, acute myeloid leukemia (AML), high-dose chemotherapy, and duration of neutropenia are significant correlative factors to BSIs, whether catheter-associated or not (18) . Another study of 327 AML patients reported 456 cases of BSI with positive blood cultures out of 956 chemotherapy treatments (47.7%, 13.2/1,000 catheter days) (19) . An additional study concluded that the risk of acquiring BSI is the highest in hematological patients with advanced AML (13.2-15.3%) (20) . Although acute leukemia and chemotherapy were not significant factors associated with CLABSI according to the findings of our present study, acute leukemia was the most frequent disease among the patients with CLABSI and all of the patients with CLABSI had CVC insertions for chemotherapy. The subclavian vein as the inser- tion site is recommended to minimize the risk of infection (7, 12) . In our study, however, there was no CLABSI in patients with CVCs inserted in the femoral vein or the cutaneous vein for peripherally inserted central catheters. The lack of infection may be due to the careful use of an appropriate selection of the insertion site for the different treatments, such as the subclavian vein and internal jugular vein for chemotherapy in patients with hematological malignancy and the femoral vein and cutaneous vein for securing vascular access. According to a univariate analysis, an age of <65 years at the time of CVC insertion is more significantly associated with the development of CLABSI than an age >65 years. One possible reason for this difference is that patients younger than 65 years may be prescribed high-dose chemotherapy, which causes more profound and prolonged neutropenia. Recent studies have reported that in-line filtration removes particulate contamination, which reduces severe complications and mortalities in neonates and in a pediatric intensive care unit (1, 2) . However, our study shows that mortality did not significantly differ between the filter and nonfilter periods. Therefore, although the use of in-line filters in CVCs for removing particles may be recommended for high-risk patients, such as neonates and children, our current study suggests that the routine use of in-line filters for infection prevention in adult patients with hematological disease may therefore be unnecessary. The mortalities of both groups reached approximately 35-40%, which seems higher than that of other studies. The increased mortality may be due to targeting older patients as a whole and including patients in the terminal phase of a disease who need CVCs for securing vascular access.
Our study is associated with some limitations, including an insufficient statistical power because of a low incidence; for stronger evidence, a randomized controlled study on a larger scale is therefore necessary. A second limitation of our study is that the effect of the cessation of in-line filters in CVCs was evaluated by the incidences of CLABSIs, which are defined as a surveillance and not a "true" CRBSI, which requires the accordance of results between blood culture and catheter tip culture. Patients with hematological malignancy develop profound and prolonged neutropenia due to intensive chemotherapy. These patients frequently present with mucosal barrier disruption and bacterial translocation. Thus, a central line-associated infection is not likely the cause of a large number of BSIs among hematology patients with febrile neutropenia (21, 22) . The criteria for a "true" CRBSI are designed to strongly implicate the CVC as the cause of the BSI; however, these criteria rely on measures that are more difficult to obtain compared to performing a survey of the incidences of CLABSIs. The CLABSI was originally intended for general medical and surgical patients. Some reports have used a modified definition of CLABSIs for patients with hematological malignancies (23) . A third limitation is that the infusion systems used between the observation periods were different because only the inline filter could not be removed from the infusion system. For analyzing the incidence of CLABSIs and mortality, the effect of these different infusion systems cannot be excluded.
In conclusion, our study revealed that the cessation of inline filters from CVCs does not significantly influence the incidence of BSIs and mortality in adult patients with hematological disease. Furthermore, neutropenia is an independent risk factor associated with BSIs. The routine use of inline filters therefore is not recommended for the prevention of BSIs in adult patients with hematological disease. Largescale randomized controlled studies are necessary, however, to confirm our results.
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